Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib

Cancer

Volumn 117, Issue 5, 2011, Pages 982-991

  Santos, Fabio P S ^a   Alvarado, Yesid ^a   Kantarjian, Hagop ^a   Verma, Dushyant ^a   O'Brien, Susan ^a   Mattiuzzi, Gloria ^a   Ravandi, Farhad ^a   Borthakur, Gautam ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anemia; Chronic myeloid leukemia; Erythropoiesis stimulating agents; Imatinib; Tyrosine kinase inhibitors

Indexed keywords

IMATINIB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; DRUG MEGADOSE; DRUG USE; EVENT FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; THROMBOSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HEMATINICS; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; POLYPHARMACY; PROGNOSIS; PYRIMIDINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952009886     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25533     Document Type: Article

References (36)

1. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820. (Pubitemid 44394987)
2. Marin D, Marktel S, Bua M, et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia. 2003;17:1448-1453. (Pubitemid 36986945)
3. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652. (Pubitemid 34815868)
4. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. (Pubitemid 36302244)
5. Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004;100:116-121. (Pubitemid 37553546)
6. Cortes J, O'Brien S, Quintas A, et al. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer. 2004;100:2396-2402. (Pubitemid 38657887)
7. Quintas-Cardama A, De Souza Santos FP, Kantarjian H, et al. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 2009;115:3935-3943.
8. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008;111:25-41.
9. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532-1542.
10. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914-924. (Pubitemid 351397066)
11. Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008;26:1040-1050.
12. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260. (Pubitemid 37324251)
13. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23:5960-5972.
14. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027-1032. (Pubitemid 46596751)
15. Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;101:97-100. (Pubitemid 36025893)
16. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873-2878. (Pubitemid 38451654)
17. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 2003;102:83-86. (Pubitemid 36759639)
18. Kantarjian HM, Talpaz M, O'Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002;8:2177-2187. (Pubitemid 34753588)
19. Quintas-Cardama A, Kantarjian HM, Ravandi F, et al. Immune modulation of minimal residual disease (MRD) in patients (pts) with chronic myelogenous leukemia (CML) in early chronic phase (CP): A randomized trial of frontline high-dose (HS) imatinib mesylate (IM) with or without pegylated-interferon (PEG-IFN) and GM-CSF [abstract]. Blood. 2006;108. Abstract 2207.
20. Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames, IA: Iowa State University Press; 1980.
21. Kaplan EL, Meire P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
22. Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
23. Cox D. Regression models and life tables. J R Stat Soc. 1972;34:187-202.
24. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22:2020-2028.
25. Quintas-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009;113:6315-6321.
26. Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood. 2008;112:3965-3973.
27. Jain N, Kantarjian HM, Fava C, et al. Imatinib dose can be safely reduced after complete cytogenetic response (CCyR) in patients (pts) with chronic myeloid leukemia (CML) in early chronic phase (CP) treated with high-dose imatinib [abstract]. Blood. 2007;110. Abstract 1043.
28. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932. (Pubitemid 30618049)
29. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022-4028.
30. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590. (Pubitemid 28385655)
31. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res. 2006;12:332-339.
32. Lai SY, Childs EE, Xi S, et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene. 2005;24:4442-4449. (Pubitemid 40961767)
33. Mohyeldin A, Lu H, Dalgard C, et al. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia. 2005;7:537-543. (Pubitemid 40791872)
34. Hardee ME, Rabbani ZN, Arcasoy MO, et al. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther. 2006;5:356-361.
35. Kumar SM, Yu H, Fong D, Acs G, Xu X. Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. Melanoma Res. 2006;16:275-283. (Pubitemid 44090171)
36. Kirschner KM, Baltensperger K. Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells. Mol Cancer Res. 2003;1:970-980. (Pubitemid 37463353)